Third trial death tied to Biogen and Eisai Alzheimer’s drug, Science reports

Science has obtained medical records that link a third death in an Alzheimer’s disease trial to lecanemab, the experimental antibody being studied in the Phase 3 trial being run by Japanese biotech Eisai (ESALY), reported Charles Piller. Eisai did not disclose the fatality at a major Alzheimer’s meeting last month where it detailed data from lecanemab’s trial and although the death came in an extension of the trial, "some scientists say it should have still been noted at the conference," according to the report, which quotes Vanderbilt University neurologist and neuroscientist Matthew Schrag as having said: "The failure of Eisai and Biogen to disclose this case … is concerning and undermines my confidence that the reported safety data is complete." Reference Link